Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialYung‐Jue Bang, Yoon‐Koo Kang, Giuseppe Aprile et al.|The Lancet|2010Cited by 7.3k
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialFlorian Lordick, Markus Moehler, Yoon‐Koo Kang et al.|The Lancet Oncology|2013Cited by 838
Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912)Narikazu Boku, Atsushi Ohtsu, Suguru Yamamoto et al.|Journal of Clinical Oncology|2007Cited by 158
Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinomaReiko Takayama, Kenji Yamao, Hidewaki Nakagawa et al.|Journal of Gastroenterology|2009Cited by 56
Serum tumor antigen REG4 as a useful diagnostic biomarker in gastric cancer.Yuji Kobayashi, Kenji Yamao, Yasumasa Niwa et al.|PubMed|2011Cited by 16